Candel Therapeutics, Inc. 8K

Candel Therapeutics reported Q2 2026 results, advanced its lead cancer immunotherapy aglatimagene toward a planned Q4 2026 BLA and phase 3 programs, expanded commercialization preparations, and disclosed higher losses alongside an extended cash runway into Q1 2028.

Candel Therapeutics, Inc. reported its second quarter 2026 financial results and provided a detailed corporate update, highlighting plans to submit a Biologics License Application for its lead candidate aglatimagene besadenovec in localized intermediate- to high-risk prostate cancer in Q4 2026, publication of pivotal phase 3 data in The Lancet Oncology showing statistically significant disease-free survival benefit, extended follow-up data presentations, and initiation of the global pivotal phase 3 AURORA trial in stage IV non-squamous NSCLC. The company also advanced development planning for linoserpaturev in recurrent glioblastoma, strengthened its commercial infrastructure by appointing Mark Sims as Chief Commercial Officer and entering a commercialization agreement with EVERSANA for a potential 2027 U.S. launch of aglatimagene, and reported a significantly higher quarterly net loss largely driven by increased R&D and commercial readiness costs and warrant liability fair value changes, with $201.6 million of cash and cash equivalents expected to fund operations into Q1 2028.

Filing Facts

CIK

1841387

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-347957

Alert Tier

6